From May 8th to 10th, the 28th China Beijing International High-tech Expo (CHITEC) was successfully held at the National Convention Center​ in Beijing. Under the theme "Technology Leads, Innovation Shares the Future," the expo featured an exhibition scale of 50,000 square meters, bringing together over 800 leading domestic and international enterprises and institutions. The event saw the on-site release of 148 scientific and technological achievements and the signing of 57 projects, with a total contract value of approximately 590 million RMB. It attracted more than 70,000 offline attendees from 72 countries and regions, alongside over 500,000 online viewers, demonstrating its significant international influence and industrial clustering effect.
 

Conference Scene
 

As a technology provider specializing in the rapid, customized development of genetically modified mouse models, MingCeler Biotech​ showcased its core TurboMice™ tetraploid complementation technology and gene-edited mouse model construction services.

 

The MingCeler Biotech​ booth drew significant attention, with many participants showing keen interest in the core advantage of TurboMice™ technology: rapid and efficient model generation.
 

In the biopharmaceutical innovation chain, the efficiency of preparing complex animal models is often a critical bottleneck that constrains R&D progress.
 

The core advantage of TurboMice™ technology lies in bypassing the time-consuming breeding and screening steps of traditional methods, significantly shortening the R&D cycle:
 

Ultra-Fast Timeline: Homozygous mice can be obtained in as little as 2 months.
 

High Precision & Efficiency: Supports efficient editing at nearly any target gene locus.
 

Complex Models: Enables delivery of homozygous mice for complex genetic models within 5 months, supporting high-speed R&D iteration.
 

The TurboMice™ platform provides robust animal model support for new drug discovery, vaccine evaluation, precision medicine, and research responses to public health emergencies.
 

Our sales managers engaged in in-depth discussions with professionals from universities, research institutes, and pharmaceutical companies, providing detailed answers regarding technical specifics and application scenarios.

During these exchanges, the team focused on practical needs such as "rapid construction of complex animal models" and "improving the efficiency of new drug pipelines." By highlighting the core advantages of TurboMice™ tetraploid complementation technology, they offered tailored solutions.
 

The atmosphere was vibrant, with many participants expressing clear intent for future collaboration after learning about the capabilities of TurboMice™.
 

 

This exhibition was not only a showcase of MingCeler Biotech's technical capabilities but also an important opportunity to deepen connections with the global biopharmaceutical community.
 

The journey continues. MingCeler Biotech​ remains committed to innovating the next generation of model animal preparation technology—TurboMice™ tetraploid complementation—to provide superior mouse models and customization services, empowering the rapid development of the biopharmaceutical industry.